Retrospective evaluation of insulin degludec/insulin aspart co-formulation therapy in patients with type 2 Diabetes Mellitus: A single-center experience

Abstract

Aim: Insulin degludec/aspart (IDegAsp) co-formulation therapy is a novel drug in Turkey and the aim of this study was toretrospectively evaluate the effects of IDegAsp therapy on glycemic control and hypoglycemia in a single tertiary center in Turkey.Material and Methods: The medical records of patients with type 2 diabetes mellitus, who were evaluated at diabetes clinic ofCerrahpaşa Medical Faculty between January and April 2018 and had started to use IDegAsp, were investigated. The demographiccharacteristics of the patients, anti-diabetic medications they were currently using, causes of treatment change, the IDegAsp doses,fasting blood glucose (FBG), HbA1c and hypoglycemic episodes at treatment onset, the third and sixth months of therapy wereevaluated.Results: Sixty-six patients (F/M:34/32; mean age:57.8±11,6years) were evaluated. Uncontrolled hyperglycemia (80.3%) and frequenthypoglycemic attacks (19,7%) were the causes of treatment change. IDegAsp was started as a single dose in 53% and doubledose in 47% of patients. Sixty-two patients (93.9%) were using insulin and the number of injections were signifiantly reduced withIDegAsp (p